Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …
Read the full story »A focus on disease-specific efforts by pharmaceutical and biotech companies
Read in depth analysis by industry experts on investing opportunities and business strategies
Learn about corporate strategies, positioning and investing opportunities
Stay on top of the industry with our industry news bulletin
Diversify to hedge your investment during economic turbulence
There will be major changes in the global pharmaceutical market and key changes in the top ten company list by 2012.
Phase I results of the first clinical trial of gene therapy for patients with advanced heart failure show the approach to be promising, with improvements in several measures of the condition’s severity.
In Phase I clinical …
Many large pharmaceutical companies plan to increase their efforts to develop HIV/AIDS drugs and diagnostics for impoverished regions.
| DJIA | 10320.10 | ||
| NASDAQ | 2200.01 | ||
| S&P 500 | 1090.10 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Jun | ||||||
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | |||
